The pressure on Medicare just keeps ramping up
Medicare is set to decide this month whether to finalize its plan to only pay for Biogen’s controversial Alzheimer’s drug, Aduhelm, when patients are enrolled in clinical trials. And advocates who oppose the idea are in the middle of a massive lobbying blitz to get them to change their minds.